FULGENT GENETICS INC (FLGT) Stock Price & Overview
NASDAQ:FLGT • US3596641098
Current stock price
The current stock price of FLGT is 15.3 USD. Today FLGT is up by 6.03%. In the past month the price increased by 3.59%. In the past year, price decreased by -14.33%.
FLGT Key Statistics
- Market Cap
- 455.175M
- P/E
- 37.32
- Fwd P/E
- N/A
- EPS (TTM)
- 0.41
- Dividend Yield
- N/A
FLGT Stock Performance
FLGT Stock Chart
FLGT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FLGT. When comparing the yearly performance of all stocks, FLGT is a bad performer in the overall market: 89.65% of all stocks are doing better.
FLGT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FLGT. While FLGT seems to be doing ok healthwise, there are quite some concerns on its profitability.
FLGT Earnings
On February 27, 2026 FLGT reported an EPS of 0.16 and a revenue of 83.34M. The company beat EPS expectations (422.88% surprise) and missed revenue expectations (-4.31% surprise).
FLGT Forecast & Estimates
9 analysts have analysed FLGT and the average price target is 24.82 USD. This implies a price increase of 62.22% is expected in the next year compared to the current price of 15.3.
For the next year, analysts expect an EPS growth of -335.51% and a revenue growth 7.26% for FLGT
FLGT Groups
Sector & Classification
FLGT Financial Highlights
Over the last trailing twelve months FLGT reported a non-GAAP Earnings per Share(EPS) of 0.41. The EPS decreased by -16.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.99% | ||
| ROE | -5.44% | ||
| Debt/Equity | 0 |
FLGT Ownership
FLGT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.79 | 101.669B | ||
| CI | THE CIGNA GROUP | 8.8 | 71.518B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 96.87 | 29.027B | ||
| LH | LABCORP HOLDINGS INC | 14.34 | 21.501B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.1 | 21.041B | ||
| GH | GUARDANT HEALTH INC | N/A | 10.31B | ||
| DVA | DAVITA INC | 10.73 | 10.023B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 28.98 | 8.72B | ||
| CHE | CHEMED CORP | 16.07 | 5.313B | ||
| OPCH | OPTION CARE HEALTH INC | 15.22 | 4.537B | ||
| HIMS | HIMS & HERS HEALTH INC | 36.38 | 4.429B | ||
| RDNT | RADNET INC | 85.94 | 4.302B | ||
| BLLN | BILLIONTOONE INC CL A | 161.56 | 3.73B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FLGT
Company Profile
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,315 full-time employees. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Company Info
IPO: 2016-09-28
FULGENT GENETICS INC
4399 Santa Anita Ave
El Monte CALIFORNIA 91780 US
CEO: Ming Hsieh
Employees: 1315
Phone: 13026587581
FULGENT GENETICS INC / FLGT FAQ
Can you describe the business of FULGENT GENETICS INC?
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,315 full-time employees. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Can you provide the latest stock price for FULGENT GENETICS INC?
The current stock price of FLGT is 15.3 USD. The price increased by 6.03% in the last trading session.
Does FULGENT GENETICS INC pay dividends?
FLGT does not pay a dividend.
What is the ChartMill technical and fundamental rating of FLGT stock?
FLGT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is FULGENT GENETICS INC (FLGT) stock traded?
FLGT stock is listed on the Nasdaq exchange.
What is the analyst forecast for FLGT stock?
9 analysts have analysed FLGT and the average price target is 24.82 USD. This implies a price increase of 62.22% is expected in the next year compared to the current price of 15.3.
Can you provide the sector and industry classification for FULGENT GENETICS INC?
FULGENT GENETICS INC (FLGT) operates in the Health Care sector and the Health Care Providers & Services industry.